• 1
    Dunne EF, Unger ER, Sternberg M et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813819.
  • 2
    de Villiers E-M, Fauquet C, Broker TR, Bernard H-U, Hausen H. Classification of papillomaviruses. Virology 2004; 324: 1727.
  • 3
    Jemal A, Simard EP, Dorell C et al. Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels. J Natl Cancer Inst 2013; 105: 175201.
  • 4
    Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine 2006; 24: S11S25.
  • 5
    Patel P et al. ‘Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008; 148: 728736.
  • 6
    D'Souza G, Wiley DJ, Li X et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48: 491499.
  • 7
    Daling JR, Madeleine MM, Johnson LG et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101: 270280.
  • 8
    Silverberg MJ, Lau B, Justice AC et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012; 54: 10261034.
  • 9
    Ryan M. An evaluation of the impact of highly active antiretroviral therapy on the pharmacoeconomics and pharmacoepidemiology of HIV infection. PhD thesis accepted 2001. University of Dublin, Trinity College.
  • 10
    Palella FJ Jr, Baker RK, Moorman AC et al. ; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 2734.
  • 11
    Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009; 199: 926935.
  • 12
    De Carvalho N, Teixeira J, Roteli-Martins CM et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7·3 years in young adult women. Vaccine 2010; 28: 62476255.
  • 13
    FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 19151927.
  • 14
    Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301314.
  • 15
    Giuliano AR et al. ‘Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364: 401411.
  • 16
    Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339: b3884.
  • 17
    Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010; 10: 845852.
  • 18
    Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis 2012; 54: 891898.
  • 19
    Sahasrabuddhe VV, Castle PE, Follansbee S et al. Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. J Infect Dis 2013; 207: 392401.
  • 20
    Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124: 23752383.
  • 21
    Sirera G, Videla S, Pinol M et al. High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men. Aids 2006; 20: 12011204.
  • 22
    Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177: 361367.
  • 23
    Nyitray AG, Carvalho da Silva RJ, Baggio ML et al. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis 2011; 204: 17111722.
  • 24
    Poynten I, Fengyi J, Templeton D et al. Prevalence, incidence, and risk factors for Human Papillomavirus 16 seropositivity in Australian homosexual men. Sex Transm Dis 2012; 39: 726732.
  • 25
    Baldwin SB, Wallace DR, Papenfuss MR, Abrahamsen M, Vaught LC, Giuliano AR. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis 2004; 31: 601607.
  • 26
    Kjaer SK, Munk C, Winther JF, Jorgensen HO, Meijer CJ, van den Brule AJ. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 2005; 14: 15281533.
  • 27
    Rock C, de Barra E, Sadlier C et al. Impact of a new vaccine clinic on hepatitis B vaccine completion and immunological response rates in an HIV-positive cohort. J Infect Public Health 2013; 6: 173178.